Harvard Bioscience Hires CEO

Harvard Bioscience Inc. hired Jeffrey A. Duchemin as its CEO. David Green, who served as the company’s interim chief executive since May 15, will continue in his capacity as the president of Harvard Bioscience until the completion of the company’s spin-off of its regenerative medicine subsidiary.

In May, former CEO Chane Graziano resigned and retired at 74 years of age and following 17 years as CEO of the company. He cited personal reasons for his departure. After 49 years in the industry, “it is the right time for me to retire,” he said of his decision at the time.

In July, Harvard Bioscience, announced that its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology Inc., or HART, filed paperwork with the U.S. Securities and Exchange Commission to separate the regenerative medicine device business from Harvard Bioscience’s core life-science research tools business.  

“Mr. Duchemin is a proven global executive with extensive experience in the fields of life-science research, diagnostic and medical devices,” said Earl Lewis, chairman of Harvard Bioscience’s board of directors. “The board of directors is excited to have Jeff join Harvard Bioscience and is looking forward to working with him to bring further success to the company.”

David Green, the company’s president, added: “As a co-founder of Harvard Bioscience, and having been its president for over 17 years, I am very pleased to introduce Jeff as the company’s new CEO. I have great confidence that Jeff can lead Harvard Bioscience to the next level of growth and value creation for all our shareholders.”

Prior to joining Harvard Bioscience, Duchemin spent 16 years with Becton Dickinson (BD) in progressive sales, marketing and executive leadership positions across BD’s three business segments—BD Medical Systems, BD Diagnostic Systems, and BD Biosciences. In October 2012, BD Biosciences, Discovery Labware was acquired by Corning Life Sciences and Duchemin served a global business director for Corning Life Sciences until his recent departure to Harvard Bioscience. He earned an MBA from Southern New Hampshire University and a bachelor’s degree in Accounting from the University of Massachusetts Dartmouth.

Holliston, Mass.-based Harvard Bioscience makes specialized products, primarily apparatus and scientific instruments used to in life-science research and regenerative medicine.